Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Entera Bio (NASDAQ:ENTX) to a sell rating in a report released on Saturday morning.

ENTX has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.00.

Entera Bio Price Performance

Entera Bio stock opened at $2.87 on Friday. The firm has a market capitalization of $141.46 million, a P/E ratio of -8.20 and a beta of 1.38. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20. The company’s 50-day moving average is $1.85 and its 200 day moving average is $1.49.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Research analysts anticipate that Entera Bio will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entera Bio

Institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP raised its stake in Entera Bio by 51.9% in the first quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock worth $228,000 after buying an additional 70,224 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Entera Bio by 338.4% in the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock valued at $526,000 after acquiring an additional 365,441 shares during the period. Superstring Capital Management LP bought a new position in shares of Entera Bio in the 4th quarter worth $33,000. Schonfeld Strategic Advisors LLC raised its position in shares of Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after acquiring an additional 29,629 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.